Cittadine Andrew 4

What Happened
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics (MNPR), had 5,254 restricted stock units (RSUs vest) on June 30, 2026. Those RSUs were converted into 5,254 common shares; the company withheld 2,309 of those shares to cover applicable withholding taxes, valued at $92.59 per share for a total tax withholding of $213,790. Net newly issued shares to Cittadine = 2,945 (5,254 vested − 2,309 withheld).

Key Details

• Transaction date: June 30, 2026; filing date: July 2, 2026.
• Vesting/conversion (derivative exercise, code M): 5,254 RSUs converted into 5,254 common shares.
• Tax withholding (code F): 2,309 shares withheld at $92.59/share, total $213,790.
• Net shares received: 2,945 shares after withholding.
• Footnotes: These shares came from scheduled RSU grants (grants dated Feb 1, 2023; Mar 4, 2025; Dec 2, 2025) that vest on a multi‑quarter schedule. Disposals labeled as derivative surrender indicate RSUs were exchanged for common stock upon vesting.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No 10b5-1 plan or late‑filing indication shown in the provided data.

Context
This was a routine RSU vesting and settlement, not an open‑market purchase or sale by the insider. The withholding of shares to cover taxes is common for RSU settlements and is recorded as a disposition (code F). The dual reporting of acquired shares and the surrendered derivative reflects issuance of stock upon vesting and cancellation of the underlying RSUs.